Investigational Drug Performs Well Against Canine Lymphoma


VetDC, a veterinary biotechnology company focused on in-licensing, developing and commercializing novel biotechnologies to address the health needs of companion animals, presented data on VDC-1101, a novel anti-proliferative agent that preferentially targets lymphoid cells and works by inhibiting cellular DNA synthesis (causing cells to die like they're supposed to die).

They presented at the 2012 American College of Veterinary Internal Medicine Forum.

The research team previously evaluated the safety and efficacy of an every three-week administration schedule of single agent VDC-1101 against canine lymphoma. The investigational drug had a good showing, demonstrating anti-tumor activity in dogs whether they had been previously treated for lymphoma or had refractory disease.

"We are very encouraged by the results of this analysis, given the high unmet need for novel, effective veterinary anti-cancer agents, particularly in the refractory setting," said Dr. David Vail, Professor of Oncology at the University of Wisconsin-Madison School of Veterinary Medicine. "These results indicate that VDC-1101 may be a powerful and convenient new therapeutic option for treating lymphoma in companion animals."

Source: MarketWatch

LymphomaInfo Social